Connect Biopharma shares surge 21.88% intraday after CEO highlights rademikibart's Phase 2 progress and $5B market potential on Bloomberg TV interview.

Connect Biopharma surged 21.88% intraday after announcing that its CEO, Barry Quart, will participate in an exclusive interview on the RedChip Small Stocks, Big Money™ show on Bloomberg TV. The interview, scheduled for November 15, highlights the company’s advancement of rademikibart, a next-generation monoclonal antibody targeting IL-4Rα, with Phase 2 "Seabreeze STAT" trials underway and top-line data expected in early 2026. The event also emphasizes Connect’s robust financial position, regulatory pathway to Phase 3 trials, and a $5 billion peak sales potential in asthma and COPD treatments. The exposure on Bloomberg TV, accessible to 73 million U.S. households, likely boosted investor confidence by showcasing the company’s clinical progress and commercial prospects, directly aligning with the intraday price surge.